Technical Objectives. [Provide an explanation of the means of achieving the result/product(s).]
Technical Objectives. The following mainframe systems have output processing feeds that need to be captured and processed; Cyberlife with IPS and work flow system (ViewStar), Paris, Vantage, LAB-Income Annuities, RPS, DSS, FMS systems, and Group Systems. Specifications are presented in 9 parts in Section 2 of this Output Processing Services SOW – Output Processing Specifications:
Technical Objectives. Proof of concept preclinical studies and preliminary toxicological studies will be completed during the Phase I efforts. The objective of the proposed Phase II efforts has the overall goal to file an exploratory IND (eIND) for a Phase 0/1 clinical study. Several specific objectives must be met to reach the overall goal to file an eIND. Objective 1: Manufacture and test clinical grade material
Technical Objectives. The Collaboration project aims to achieve the following objectives:
Technical Objectives. KRASNOYARSK-45
Technical Objectives. Objective 1: Perform the Phase I and PK clinical trial of IPdR-mediated radiosensitization.
Technical Objectives. Objectives: [* 1.5 pages omitted] II. DELIVERABLES [*] [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
Technical Objectives. The EaaS solution shall achieve the technical objectives to achieve a high degree of confidentiality, integrity, reliability and availability in accordance with the GSA EaaS BPA.
Technical Objectives. The technical objectives of this CRADA project are to develop a new therapeutic entity with activity against gram-negative category A and B biothreat agents. The therapeutic will be a small molecule that can be administered intravenously (i.v.), preferably once- or twice-a-day and will be available for use both as a prophylactic and as a therapeutic against a wide range of biodefense pathogens. These include the gram-negative biodefense pathogens: Escherichia coli, Salmonella (enteritis and Typhi), Shigella dysenteriae, Yersinia pestis, Burkholderia pseudomallei, Campylobacter jejuni and Francisella tularensis, as well as potentially the Category A gram-positive pathogen Bacillus anthracis. This new therapeutic will act through inhibition of bacterial DNA topoisomerase IV and DNA gyrase (ParE and GyrB, respectively). 08IS1120 SOW App. A 3/10 TC02128.0 Trius Therapeutics, Inc.
